Global Neoantigen Vaccine Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Page: 121

Published Date: 12 Jan 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

According to our (Global Info Research) latest study, the global Neoantigen Vaccine market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report is a detailed and comprehensive analysis for global Neoantigen Vaccine market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:
Global Neoantigen Vaccine market size and forecasts, in consumption value ($ Million), 2018-2029
Global Neoantigen Vaccine market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Neoantigen Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Neoantigen Vaccine market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Neoantigen Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Neoantigen Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Merck & Co Inc, Eli Lilly and Company, BioNTech and Roche Holding AG, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation
Neoantigen Vaccine market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Personalized Vaccine
    Off-the shelf Vaccine

Market segment by Application
    Lung Cancer
    Melanoma Cancer
    Gastrointestinal Cancer
    Brain Cancer
    Others

Market segment by players, this report covers
    Pfizer
    Merck & Co Inc
    Eli Lilly and Company
    BioNTech
    Roche Holding AG
    OSE Immunotherapeutics
    Gritstone Bio
    Moderna
    Avidea Technologies
    Vaccibody AS
    Agenus Inc
    Novogene
    ZIOPHARM Oncology
    ISA Pharmaceuticals
    BrightPath Biotherapeutics
    Vaximm AG
    Medigene AG
    Genocea Biosciences Inc
    Advaxis
    Nouscom

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Neoantigen Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Neoantigen Vaccine, with revenue, gross margin and global market share of Neoantigen Vaccine from 2018 to 2023.
Chapter 3, the Neoantigen Vaccine competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Neoantigen Vaccine market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Neoantigen Vaccine.
Chapter 13, to describe Neoantigen Vaccine research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Neoantigen Vaccine
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Neoantigen Vaccine by Type
        1.3.1 Overview: Global Neoantigen Vaccine Market Size by Type: 2018 Versus 2022 Versus 2029
        1.3.2 Global Neoantigen Vaccine Consumption Value Market Share by Type in 2022
        1.3.3 Personalized Vaccine
        1.3.4 Off-the shelf Vaccine
    1.4 Global Neoantigen Vaccine Market by Application
        1.4.1 Overview: Global Neoantigen Vaccine Market Size by Application: 2018 Versus 2022 Versus 2029
        1.4.2 Lung Cancer
        1.4.3 Melanoma Cancer
        1.4.4 Gastrointestinal Cancer
        1.4.5 Brain Cancer
        1.4.6 Others
    1.5 Global Neoantigen Vaccine Market Size & Forecast
    1.6 Global Neoantigen Vaccine Market Size and Forecast by Region
        1.6.1 Global Neoantigen Vaccine Market Size by Region: 2018 VS 2022 VS 2029
        1.6.2 Global Neoantigen Vaccine Market Size by Region, (2018-2029)
        1.6.3 North America Neoantigen Vaccine Market Size and Prospect (2018-2029)
        1.6.4 Europe Neoantigen Vaccine Market Size and Prospect (2018-2029)
        1.6.5 Asia-Pacific Neoantigen Vaccine Market Size and Prospect (2018-2029)
        1.6.6 South America Neoantigen Vaccine Market Size and Prospect (2018-2029)
        1.6.7 Middle East and Africa Neoantigen Vaccine Market Size and Prospect (2018-2029)

2 Company Profiles
    2.1 Pfizer
        2.1.1 Pfizer Details
        2.1.2 Pfizer Major Business
        2.1.3 Pfizer Neoantigen Vaccine Product and Solutions
        2.1.4 Pfizer Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
        2.1.5 Pfizer Recent Developments and Future Plans
    2.2 Merck & Co Inc
        2.2.1 Merck & Co Inc Details
        2.2.2 Merck & Co Inc Major Business
        2.2.3 Merck & Co Inc Neoantigen Vaccine Product and Solutions
        2.2.4 Merck & Co Inc Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
        2.2.5 Merck & Co Inc Recent Developments and Future Plans
    2.3 Eli Lilly and Company
        2.3.1 Eli Lilly and Company Details
        2.3.2 Eli Lilly and Company Major Business
        2.3.3 Eli Lilly and Company Neoantigen Vaccine Product and Solutions
        2.3.4 Eli Lilly and Company Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
        2.3.5 Eli Lilly and Company Recent Developments and Future Plans
    2.4 BioNTech
        2.4.1 BioNTech Details
        2.4.2 BioNTech Major Business
        2.4.3 BioNTech Neoantigen Vaccine Product and Solutions
        2.4.4 BioNTech Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
        2.4.5 BioNTech Recent Developments and Future Plans
    2.5 Roche Holding AG
        2.5.1 Roche Holding AG Details
        2.5.2 Roche Holding AG Major Business
        2.5.3 Roche Holding AG Neoantigen Vaccine Product and Solutions
        2.5.4 Roche Holding AG Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
        2.5.5 Roche Holding AG Recent Developments and Future Plans
    2.6 OSE Immunotherapeutics
        2.6.1 OSE Immunotherapeutics Details
        2.6.2 OSE Immunotherapeutics Major Business
        2.6.3 OSE Immunotherapeutics Neoantigen Vaccine Product and Solutions
        2.6.4 OSE Immunotherapeutics Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
        2.6.5 OSE Immunotherapeutics Recent Developments and Future Plans
    2.7 Gritstone Bio
        2.7.1 Gritstone Bio Details
        2.7.2 Gritstone Bio Major Business
        2.7.3 Gritstone Bio Neoantigen Vaccine Product and Solutions
        2.7.4 Gritstone Bio Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
        2.7.5 Gritstone Bio Recent Developments and Future Plans
    2.8 Moderna
        2.8.1 Moderna Details
        2.8.2 Moderna Major Business
        2.8.3 Moderna Neoantigen Vaccine Product and Solutions
        2.8.4 Moderna Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
        2.8.5 Moderna Recent Developments and Future Plans
    2.9 Avidea Technologies
        2.9.1 Avidea Technologies Details
        2.9.2 Avidea Technologies Major Business
        2.9.3 Avidea Technologies Neoantigen Vaccine Product and Solutions
        2.9.4 Avidea Technologies Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
        2.9.5 Avidea Technologies Recent Developments and Future Plans
    2.10 Vaccibody AS
        2.10.1 Vaccibody AS Details
        2.10.2 Vaccibody AS Major Business
        2.10.3 Vaccibody AS Neoantigen Vaccine Product and Solutions
        2.10.4 Vaccibody AS Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
        2.10.5 Vaccibody AS Recent Developments and Future Plans
    2.11 Agenus Inc
        2.11.1 Agenus Inc Details
        2.11.2 Agenus Inc Major Business
        2.11.3 Agenus Inc Neoantigen Vaccine Product and Solutions
        2.11.4 Agenus Inc Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
        2.11.5 Agenus Inc Recent Developments and Future Plans
    2.12 Novogene
        2.12.1 Novogene Details
        2.12.2 Novogene Major Business
        2.12.3 Novogene Neoantigen Vaccine Product and Solutions
        2.12.4 Novogene Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
        2.12.5 Novogene Recent Developments and Future Plans
    2.13 ZIOPHARM Oncology
        2.13.1 ZIOPHARM Oncology Details
        2.13.2 ZIOPHARM Oncology Major Business
        2.13.3 ZIOPHARM Oncology Neoantigen Vaccine Product and Solutions
        2.13.4 ZIOPHARM Oncology Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
        2.13.5 ZIOPHARM Oncology Recent Developments and Future Plans
    2.14 ISA Pharmaceuticals
        2.14.1 ISA Pharmaceuticals Details
        2.14.2 ISA Pharmaceuticals Major Business
        2.14.3 ISA Pharmaceuticals Neoantigen Vaccine Product and Solutions
        2.14.4 ISA Pharmaceuticals Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
        2.14.5 ISA Pharmaceuticals Recent Developments and Future Plans
    2.15 BrightPath Biotherapeutics
        2.15.1 BrightPath Biotherapeutics Details
        2.15.2 BrightPath Biotherapeutics Major Business
        2.15.3 BrightPath Biotherapeutics Neoantigen Vaccine Product and Solutions
        2.15.4 BrightPath Biotherapeutics Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
        2.15.5 BrightPath Biotherapeutics Recent Developments and Future Plans
    2.16 Vaximm AG
        2.16.1 Vaximm AG Details
        2.16.2 Vaximm AG Major Business
        2.16.3 Vaximm AG Neoantigen Vaccine Product and Solutions
        2.16.4 Vaximm AG Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
        2.16.5 Vaximm AG Recent Developments and Future Plans
    2.17 Medigene AG
        2.17.1 Medigene AG Details
        2.17.2 Medigene AG Major Business
        2.17.3 Medigene AG Neoantigen Vaccine Product and Solutions
        2.17.4 Medigene AG Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
        2.17.5 Medigene AG Recent Developments and Future Plans
    2.18 Genocea Biosciences Inc
        2.18.1 Genocea Biosciences Inc Details
        2.18.2 Genocea Biosciences Inc Major Business
        2.18.3 Genocea Biosciences Inc Neoantigen Vaccine Product and Solutions
        2.18.4 Genocea Biosciences Inc Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
        2.18.5 Genocea Biosciences Inc Recent Developments and Future Plans
    2.19 Advaxis
        2.19.1 Advaxis Details
        2.19.2 Advaxis Major Business
        2.19.3 Advaxis Neoantigen Vaccine Product and Solutions
        2.19.4 Advaxis Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
        2.19.5 Advaxis Recent Developments and Future Plans
    2.20 Nouscom
        2.20.1 Nouscom Details
        2.20.2 Nouscom Major Business
        2.20.3 Nouscom Neoantigen Vaccine Product and Solutions
        2.20.4 Nouscom Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
        2.20.5 Nouscom Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Neoantigen Vaccine Revenue and Share by Players (2018-2023)
    3.2 Market Share Analysis (2022)
        3.2.1 Market Share of Neoantigen Vaccine by Company Revenue
        3.2.2 Top 3 Neoantigen Vaccine Players Market Share in 2022
        3.2.3 Top 6 Neoantigen Vaccine Players Market Share in 2022
    3.3 Neoantigen Vaccine Market: Overall Company Footprint Analysis
        3.3.1 Neoantigen Vaccine Market: Region Footprint
        3.3.2 Neoantigen Vaccine Market: Company Product Type Footprint
        3.3.3 Neoantigen Vaccine Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global Neoantigen Vaccine Consumption Value and Market Share by Type (2018-2023)
    4.2 Global Neoantigen Vaccine Market Forecast by Type (2024-2029)

5 Market Size Segment by Application
    5.1 Global Neoantigen Vaccine Consumption Value Market Share by Application (2018-2023)
    5.2 Global Neoantigen Vaccine Market Forecast by Application (2024-2029)

6 North America
    6.1 North America Neoantigen Vaccine Consumption Value by Type (2018-2029)
    6.2 North America Neoantigen Vaccine Consumption Value by Application (2018-2029)
    6.3 North America Neoantigen Vaccine Market Size by Country
        6.3.1 North America Neoantigen Vaccine Consumption Value by Country (2018-2029)
        6.3.2 United States Neoantigen Vaccine Market Size and Forecast (2018-2029)
        6.3.3 Canada Neoantigen Vaccine Market Size and Forecast (2018-2029)
        6.3.4 Mexico Neoantigen Vaccine Market Size and Forecast (2018-2029)

7 Europe
    7.1 Europe Neoantigen Vaccine Consumption Value by Type (2018-2029)
    7.2 Europe Neoantigen Vaccine Consumption Value by Application (2018-2029)
    7.3 Europe Neoantigen Vaccine Market Size by Country
        7.3.1 Europe Neoantigen Vaccine Consumption Value by Country (2018-2029)
        7.3.2 Germany Neoantigen Vaccine Market Size and Forecast (2018-2029)
        7.3.3 France Neoantigen Vaccine Market Size and Forecast (2018-2029)
        7.3.4 United Kingdom Neoantigen Vaccine Market Size and Forecast (2018-2029)
        7.3.5 Russia Neoantigen Vaccine Market Size and Forecast (2018-2029)
        7.3.6 Italy Neoantigen Vaccine Market Size and Forecast (2018-2029)

8 Asia-Pacific
    8.1 Asia-Pacific Neoantigen Vaccine Consumption Value by Type (2018-2029)
    8.2 Asia-Pacific Neoantigen Vaccine Consumption Value by Application (2018-2029)
    8.3 Asia-Pacific Neoantigen Vaccine Market Size by Region
        8.3.1 Asia-Pacific Neoantigen Vaccine Consumption Value by Region (2018-2029)
        8.3.2 China Neoantigen Vaccine Market Size and Forecast (2018-2029)
        8.3.3 Japan Neoantigen Vaccine Market Size and Forecast (2018-2029)
        8.3.4 South Korea Neoantigen Vaccine Market Size and Forecast (2018-2029)
        8.3.5 India Neoantigen Vaccine Market Size and Forecast (2018-2029)
        8.3.6 Southeast Asia Neoantigen Vaccine Market Size and Forecast (2018-2029)
        8.3.7 Australia Neoantigen Vaccine Market Size and Forecast (2018-2029)

9 South America
    9.1 South America Neoantigen Vaccine Consumption Value by Type (2018-2029)
    9.2 South America Neoantigen Vaccine Consumption Value by Application (2018-2029)
    9.3 South America Neoantigen Vaccine Market Size by Country
        9.3.1 South America Neoantigen Vaccine Consumption Value by Country (2018-2029)
        9.3.2 Brazil Neoantigen Vaccine Market Size and Forecast (2018-2029)
        9.3.3 Argentina Neoantigen Vaccine Market Size and Forecast (2018-2029)

10 Middle East & Africa
    10.1 Middle East & Africa Neoantigen Vaccine Consumption Value by Type (2018-2029)
    10.2 Middle East & Africa Neoantigen Vaccine Consumption Value by Application (2018-2029)
    10.3 Middle East & Africa Neoantigen Vaccine Market Size by Country
        10.3.1 Middle East & Africa Neoantigen Vaccine Consumption Value by Country (2018-2029)
        10.3.2 Turkey Neoantigen Vaccine Market Size and Forecast (2018-2029)
        10.3.3 Saudi Arabia Neoantigen Vaccine Market Size and Forecast (2018-2029)
        10.3.4 UAE Neoantigen Vaccine Market Size and Forecast (2018-2029)

11 Market Dynamics
    11.1 Neoantigen Vaccine Market Drivers
    11.2 Neoantigen Vaccine Market Restraints
    11.3 Neoantigen Vaccine Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry
    11.5 Influence of COVID-19 and Russia-Ukraine War
        11.5.1 Influence of COVID-19
        11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis
    12.1 Neoantigen Vaccine Industry Chain
    12.2 Neoantigen Vaccine Upstream Analysis
    12.3 Neoantigen Vaccine Midstream Analysis
    12.4 Neoantigen Vaccine Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Neoantigen Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 2. Global Neoantigen Vaccine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 3. Global Neoantigen Vaccine Consumption Value by Region (2018-2023) & (USD Million)
    Table 4. Global Neoantigen Vaccine Consumption Value by Region (2024-2029) & (USD Million)
    Table 5. Pfizer Company Information, Head Office, and Major Competitors
    Table 6. Pfizer Major Business
    Table 7. Pfizer Neoantigen Vaccine Product and Solutions
    Table 8. Pfizer Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 9. Pfizer Recent Developments and Future Plans
    Table 10. Merck & Co Inc Company Information, Head Office, and Major Competitors
    Table 11. Merck & Co Inc Major Business
    Table 12. Merck & Co Inc Neoantigen Vaccine Product and Solutions
    Table 13. Merck & Co Inc Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 14. Merck & Co Inc Recent Developments and Future Plans
    Table 15. Eli Lilly and Company Company Information, Head Office, and Major Competitors
    Table 16. Eli Lilly and Company Major Business
    Table 17. Eli Lilly and Company Neoantigen Vaccine Product and Solutions
    Table 18. Eli Lilly and Company Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 19. Eli Lilly and Company Recent Developments and Future Plans
    Table 20. BioNTech Company Information, Head Office, and Major Competitors
    Table 21. BioNTech Major Business
    Table 22. BioNTech Neoantigen Vaccine Product and Solutions
    Table 23. BioNTech Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 24. BioNTech Recent Developments and Future Plans
    Table 25. Roche Holding AG Company Information, Head Office, and Major Competitors
    Table 26. Roche Holding AG Major Business
    Table 27. Roche Holding AG Neoantigen Vaccine Product and Solutions
    Table 28. Roche Holding AG Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 29. Roche Holding AG Recent Developments and Future Plans
    Table 30. OSE Immunotherapeutics Company Information, Head Office, and Major Competitors
    Table 31. OSE Immunotherapeutics Major Business
    Table 32. OSE Immunotherapeutics Neoantigen Vaccine Product and Solutions
    Table 33. OSE Immunotherapeutics Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 34. OSE Immunotherapeutics Recent Developments and Future Plans
    Table 35. Gritstone Bio Company Information, Head Office, and Major Competitors
    Table 36. Gritstone Bio Major Business
    Table 37. Gritstone Bio Neoantigen Vaccine Product and Solutions
    Table 38. Gritstone Bio Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 39. Gritstone Bio Recent Developments and Future Plans
    Table 40. Moderna Company Information, Head Office, and Major Competitors
    Table 41. Moderna Major Business
    Table 42. Moderna Neoantigen Vaccine Product and Solutions
    Table 43. Moderna Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 44. Moderna Recent Developments and Future Plans
    Table 45. Avidea Technologies Company Information, Head Office, and Major Competitors
    Table 46. Avidea Technologies Major Business
    Table 47. Avidea Technologies Neoantigen Vaccine Product and Solutions
    Table 48. Avidea Technologies Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 49. Avidea Technologies Recent Developments and Future Plans
    Table 50. Vaccibody AS Company Information, Head Office, and Major Competitors
    Table 51. Vaccibody AS Major Business
    Table 52. Vaccibody AS Neoantigen Vaccine Product and Solutions
    Table 53. Vaccibody AS Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 54. Vaccibody AS Recent Developments and Future Plans
    Table 55. Agenus Inc Company Information, Head Office, and Major Competitors
    Table 56. Agenus Inc Major Business
    Table 57. Agenus Inc Neoantigen Vaccine Product and Solutions
    Table 58. Agenus Inc Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 59. Agenus Inc Recent Developments and Future Plans
    Table 60. Novogene Company Information, Head Office, and Major Competitors
    Table 61. Novogene Major Business
    Table 62. Novogene Neoantigen Vaccine Product and Solutions
    Table 63. Novogene Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 64. Novogene Recent Developments and Future Plans
    Table 65. ZIOPHARM Oncology Company Information, Head Office, and Major Competitors
    Table 66. ZIOPHARM Oncology Major Business
    Table 67. ZIOPHARM Oncology Neoantigen Vaccine Product and Solutions
    Table 68. ZIOPHARM Oncology Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 69. ZIOPHARM Oncology Recent Developments and Future Plans
    Table 70. ISA Pharmaceuticals Company Information, Head Office, and Major Competitors
    Table 71. ISA Pharmaceuticals Major Business
    Table 72. ISA Pharmaceuticals Neoantigen Vaccine Product and Solutions
    Table 73. ISA Pharmaceuticals Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 74. ISA Pharmaceuticals Recent Developments and Future Plans
    Table 75. BrightPath Biotherapeutics Company Information, Head Office, and Major Competitors
    Table 76. BrightPath Biotherapeutics Major Business
    Table 77. BrightPath Biotherapeutics Neoantigen Vaccine Product and Solutions
    Table 78. BrightPath Biotherapeutics Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 79. BrightPath Biotherapeutics Recent Developments and Future Plans
    Table 80. Vaximm AG Company Information, Head Office, and Major Competitors
    Table 81. Vaximm AG Major Business
    Table 82. Vaximm AG Neoantigen Vaccine Product and Solutions
    Table 83. Vaximm AG Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 84. Vaximm AG Recent Developments and Future Plans
    Table 85. Medigene AG Company Information, Head Office, and Major Competitors
    Table 86. Medigene AG Major Business
    Table 87. Medigene AG Neoantigen Vaccine Product and Solutions
    Table 88. Medigene AG Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 89. Medigene AG Recent Developments and Future Plans
    Table 90. Genocea Biosciences Inc Company Information, Head Office, and Major Competitors
    Table 91. Genocea Biosciences Inc Major Business
    Table 92. Genocea Biosciences Inc Neoantigen Vaccine Product and Solutions
    Table 93. Genocea Biosciences Inc Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 94. Genocea Biosciences Inc Recent Developments and Future Plans
    Table 95. Advaxis Company Information, Head Office, and Major Competitors
    Table 96. Advaxis Major Business
    Table 97. Advaxis Neoantigen Vaccine Product and Solutions
    Table 98. Advaxis Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 99. Advaxis Recent Developments and Future Plans
    Table 100. Nouscom Company Information, Head Office, and Major Competitors
    Table 101. Nouscom Major Business
    Table 102. Nouscom Neoantigen Vaccine Product and Solutions
    Table 103. Nouscom Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 104. Nouscom Recent Developments and Future Plans
    Table 105. Global Neoantigen Vaccine Revenue (USD Million) by Players (2018-2023)
    Table 106. Global Neoantigen Vaccine Revenue Share by Players (2018-2023)
    Table 107. Breakdown of Neoantigen Vaccine by Company Type (Tier 1, Tier 2, and Tier 3)
    Table 108. Market Position of Players in Neoantigen Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
    Table 109. Head Office of Key Neoantigen Vaccine Players
    Table 110. Neoantigen Vaccine Market: Company Product Type Footprint
    Table 111. Neoantigen Vaccine Market: Company Product Application Footprint
    Table 112. Neoantigen Vaccine New Market Entrants and Barriers to Market Entry
    Table 113. Neoantigen Vaccine Mergers, Acquisition, Agreements, and Collaborations
    Table 114. Global Neoantigen Vaccine Consumption Value (USD Million) by Type (2018-2023)
    Table 115. Global Neoantigen Vaccine Consumption Value Share by Type (2018-2023)
    Table 116. Global Neoantigen Vaccine Consumption Value Forecast by Type (2024-2029)
    Table 117. Global Neoantigen Vaccine Consumption Value by Application (2018-2023)
    Table 118. Global Neoantigen Vaccine Consumption Value Forecast by Application (2024-2029)
    Table 119. North America Neoantigen Vaccine Consumption Value by Type (2018-2023) & (USD Million)
    Table 120. North America Neoantigen Vaccine Consumption Value by Type (2024-2029) & (USD Million)
    Table 121. North America Neoantigen Vaccine Consumption Value by Application (2018-2023) & (USD Million)
    Table 122. North America Neoantigen Vaccine Consumption Value by Application (2024-2029) & (USD Million)
    Table 123. North America Neoantigen Vaccine Consumption Value by Country (2018-2023) & (USD Million)
    Table 124. North America Neoantigen Vaccine Consumption Value by Country (2024-2029) & (USD Million)
    Table 125. Europe Neoantigen Vaccine Consumption Value by Type (2018-2023) & (USD Million)
    Table 126. Europe Neoantigen Vaccine Consumption Value by Type (2024-2029) & (USD Million)
    Table 127. Europe Neoantigen Vaccine Consumption Value by Application (2018-2023) & (USD Million)
    Table 128. Europe Neoantigen Vaccine Consumption Value by Application (2024-2029) & (USD Million)
    Table 129. Europe Neoantigen Vaccine Consumption Value by Country (2018-2023) & (USD Million)
    Table 130. Europe Neoantigen Vaccine Consumption Value by Country (2024-2029) & (USD Million)
    Table 131. Asia-Pacific Neoantigen Vaccine Consumption Value by Type (2018-2023) & (USD Million)
    Table 132. Asia-Pacific Neoantigen Vaccine Consumption Value by Type (2024-2029) & (USD Million)
    Table 133. Asia-Pacific Neoantigen Vaccine Consumption Value by Application (2018-2023) & (USD Million)
    Table 134. Asia-Pacific Neoantigen Vaccine Consumption Value by Application (2024-2029) & (USD Million)
    Table 135. Asia-Pacific Neoantigen Vaccine Consumption Value by Region (2018-2023) & (USD Million)
    Table 136. Asia-Pacific Neoantigen Vaccine Consumption Value by Region (2024-2029) & (USD Million)
    Table 137. South America Neoantigen Vaccine Consumption Value by Type (2018-2023) & (USD Million)
    Table 138. South America Neoantigen Vaccine Consumption Value by Type (2024-2029) & (USD Million)
    Table 139. South America Neoantigen Vaccine Consumption Value by Application (2018-2023) & (USD Million)
    Table 140. South America Neoantigen Vaccine Consumption Value by Application (2024-2029) & (USD Million)
    Table 141. South America Neoantigen Vaccine Consumption Value by Country (2018-2023) & (USD Million)
    Table 142. South America Neoantigen Vaccine Consumption Value by Country (2024-2029) & (USD Million)
    Table 143. Middle East & Africa Neoantigen Vaccine Consumption Value by Type (2018-2023) & (USD Million)
    Table 144. Middle East & Africa Neoantigen Vaccine Consumption Value by Type (2024-2029) & (USD Million)
    Table 145. Middle East & Africa Neoantigen Vaccine Consumption Value by Application (2018-2023) & (USD Million)
    Table 146. Middle East & Africa Neoantigen Vaccine Consumption Value by Application (2024-2029) & (USD Million)
    Table 147. Middle East & Africa Neoantigen Vaccine Consumption Value by Country (2018-2023) & (USD Million)
    Table 148. Middle East & Africa Neoantigen Vaccine Consumption Value by Country (2024-2029) & (USD Million)
    Table 149. Neoantigen Vaccine Raw Material
    Table 150. Key Suppliers of Neoantigen Vaccine Raw Materials
List of Figures
    Figure 1. Neoantigen Vaccine Picture
    Figure 2. Global Neoantigen Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 3. Global Neoantigen Vaccine Consumption Value Market Share by Type in 2022
    Figure 4. Personalized Vaccine
    Figure 5. Off-the shelf Vaccine
    Figure 6. Global Neoantigen Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 7. Neoantigen Vaccine Consumption Value Market Share by Application in 2022
    Figure 8. Lung Cancer Picture
    Figure 9. Melanoma Cancer Picture
    Figure 10. Gastrointestinal Cancer Picture
    Figure 11. Brain Cancer Picture
    Figure 12. Others Picture
    Figure 13. Global Neoantigen Vaccine Consumption Value, (USD Million): 2018 & 2022 & 2029
    Figure 14. Global Neoantigen Vaccine Consumption Value and Forecast (2018-2029) & (USD Million)
    Figure 15. Global Market Neoantigen Vaccine Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
    Figure 16. Global Neoantigen Vaccine Consumption Value Market Share by Region (2018-2029)
    Figure 17. Global Neoantigen Vaccine Consumption Value Market Share by Region in 2022
    Figure 18. North America Neoantigen Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 19. Europe Neoantigen Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 20. Asia-Pacific Neoantigen Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 21. South America Neoantigen Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 22. Middle East and Africa Neoantigen Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 23. Global Neoantigen Vaccine Revenue Share by Players in 2022
    Figure 24. Neoantigen Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
    Figure 25. Global Top 3 Players Neoantigen Vaccine Market Share in 2022
    Figure 26. Global Top 6 Players Neoantigen Vaccine Market Share in 2022
    Figure 27. Global Neoantigen Vaccine Consumption Value Share by Type (2018-2023)
    Figure 28. Global Neoantigen Vaccine Market Share Forecast by Type (2024-2029)
    Figure 29. Global Neoantigen Vaccine Consumption Value Share by Application (2018-2023)
    Figure 30. Global Neoantigen Vaccine Market Share Forecast by Application (2024-2029)
    Figure 31. North America Neoantigen Vaccine Consumption Value Market Share by Type (2018-2029)
    Figure 32. North America Neoantigen Vaccine Consumption Value Market Share by Application (2018-2029)
    Figure 33. North America Neoantigen Vaccine Consumption Value Market Share by Country (2018-2029)
    Figure 34. United States Neoantigen Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 35. Canada Neoantigen Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 36. Mexico Neoantigen Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 37. Europe Neoantigen Vaccine Consumption Value Market Share by Type (2018-2029)
    Figure 38. Europe Neoantigen Vaccine Consumption Value Market Share by Application (2018-2029)
    Figure 39. Europe Neoantigen Vaccine Consumption Value Market Share by Country (2018-2029)
    Figure 40. Germany Neoantigen Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 41. France Neoantigen Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 42. United Kingdom Neoantigen Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 43. Russia Neoantigen Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 44. Italy Neoantigen Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 45. Asia-Pacific Neoantigen Vaccine Consumption Value Market Share by Type (2018-2029)
    Figure 46. Asia-Pacific Neoantigen Vaccine Consumption Value Market Share by Application (2018-2029)
    Figure 47. Asia-Pacific Neoantigen Vaccine Consumption Value Market Share by Region (2018-2029)
    Figure 48. China Neoantigen Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 49. Japan Neoantigen Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 50. South Korea Neoantigen Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 51. India Neoantigen Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 52. Southeast Asia Neoantigen Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 53. Australia Neoantigen Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 54. South America Neoantigen Vaccine Consumption Value Market Share by Type (2018-2029)
    Figure 55. South America Neoantigen Vaccine Consumption Value Market Share by Application (2018-2029)
    Figure 56. South America Neoantigen Vaccine Consumption Value Market Share by Country (2018-2029)
    Figure 57. Brazil Neoantigen Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 58. Argentina Neoantigen Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 59. Middle East and Africa Neoantigen Vaccine Consumption Value Market Share by Type (2018-2029)
    Figure 60. Middle East and Africa Neoantigen Vaccine Consumption Value Market Share by Application (2018-2029)
    Figure 61. Middle East and Africa Neoantigen Vaccine Consumption Value Market Share by Country (2018-2029)
    Figure 62. Turkey Neoantigen Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 63. Saudi Arabia Neoantigen Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 64. UAE Neoantigen Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 65. Neoantigen Vaccine Market Drivers
    Figure 66. Neoantigen Vaccine Market Restraints
    Figure 67. Neoantigen Vaccine Market Trends
    Figure 68. Porters Five Forces Analysis
    Figure 69. Manufacturing Cost Structure Analysis of Neoantigen Vaccine in 2022
    Figure 70. Manufacturing Process Analysis of Neoantigen Vaccine
    Figure 71. Neoantigen Vaccine Industrial Chain
    Figure 72. Methodology
    Figure 73. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Pfizer
Merck & Co Inc
Eli Lilly and Company
BioNTech
Roche Holding AG
OSE Immunotherapeutics
Gritstone Bio
Moderna
Avidea Technologies
Vaccibody AS
Agenus Inc
Novogene
ZIOPHARM Oncology
ISA Pharmaceuticals
BrightPath Biotherapeutics
Vaximm AG
Medigene AG
Genocea Biosciences Inc
Advaxis
Nouscom

Related Reports

Global Neoantigen Vaccine Supply, Demand and Key Producers, 2023-2029

Global Neoantigen Vaccine Supply, Demand and Key Producers, 2023-2029

date 04 Feb 2023

date Pharma & Healthcare

The global Neoantigen Vaccine market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Global Neoantigen Vaccine Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Neoantigen Vaccine Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 02 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Neoantigen Vaccine market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

Global Neoantigen Vaccine Supply, Demand and Key Producers, 2024-2030

Global Neoantigen Vaccine Supply, Demand and Key Producers, 2024-2030

date 10 Feb 2024

date Pharma & Healthcare

The global Neoantigen Vaccine market size is expected to reach $ million by 2030, rising at a market growth of % CAGR during the forecast period (2024-2030).

Product Tags

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>